HPV Negative

n=37

HPV Positive

n=36

p

Median (Range)

n (%)

Median (Range)

n (%)

Age

56 yrs

(29-82)

60 yrs

(33-76)

0.74

Gender

Female

17 (46)

3 (8)

<0.01

Primary Site

Oral Cavity

Oropharynx

33 (89)

4 (11)

2 (6)

34 (94)

<0.01

Tobacco Use History

None

<10 pack-years

>10 pack-years

6 (16)

7 (19)

24 (65)

15 (43)

5 (14)

15 (43)

0.04

PET/CT Staging

22 (60)

31 (86)

0.01

AJCC Clinical Stage

1-2

3

4a

15 (40)

13 (35)

9 (24)

0 (0)

10 (28)

26 (72)

<0.01

Interval, Biopsy to Resection

39 days

(7-90)

32 days

(0-56)

<0.01

Tumor Grade

1-2

3

31 (84)

6 (16)

12 (33)

24 (67)

<0.01

Tumor Size

3.1 cm

(0.9-6.7)

1.8 cm

(0.3-4.7)

<0.01

Pathologic Nodal Tumor Size (largest)

1.25 cm

(0.2-4.3)

3.5 cm

(0.9-6.5)

<0.01

# LNs Involved

2

(0-5)

2

(1-32)

0.57

% LNs Involved

8%

(1.6-20)

6%

(1.5-56)

0.69

Extranodal Extension

20 (54)

17 (47)

0.56

Perineural Invasion

25 (68)

6 (18)

<0.01

Lymphovascular Invasion

18 (51)

15 (43)

0.47

AJCC Pathologic Stage

1-3

4

11 (30)

26 (70)

11 (31)

35 (69)

0.94

Interval, Resection to RT

45.5 days

(27-117)

47.5 days

(33-77)

0.55

Interval, RT Start to End

46 days

(31-111)

46.5 days

(34-60)

0.70

RT Dose

6600 cGy

(5000-6996)

6600 cGy

(5000-7200)

Concurrent Chemotherapy

11 (30)

15 (42)

0.29

OTT

94 days

(69-185)

93 days

(74-120)

0.69